世界の臨床試験市場2021-2028:フェーズ別(フェーズ1、フェーズ2、フェーズ3、フェーズ4)、研究デザイン別(介入性、観察、拡張アクセス)、疾患別、地域別

◆英語タイトル:Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Indication, By Region, And Segment Forecasts, 2021 - 2028
◆商品コード:GV21JU038
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2021年6月9日
◆ページ数:120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥684,250見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥799,250見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥1,029,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Grand View Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

グランドビューリサーチ社は、世界の臨床試験市場規模が2028年までに693億ドルに達すると予測しています。2021年から2028年までに年平均5.7%成長する見通しです。本市場調査レポートは、臨床試験の世界市場を調査対象とし、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、フェーズ別(フェーズ1、フェーズ2、フェーズ3、フェーズ4)分析、研究デザイン別(介入性、観察、拡張アクセス)分析、疾患別(自己免疫・炎症、疼痛処理、腫瘍、糖尿病、肥満、その他)分析、地域別分析、競争分析などを徹底分析したものです。
・調査手法・範囲
・エグゼクティブサマリー
・市場変動・動向・範囲
・世界の臨床試験市場規模:フェーズ別(フェーズ1、フェーズ2、フェーズ3、フェーズ4)
・世界の臨床試験市場規模:研究デザイン別(介入性、観察、拡張アクセス)
・世界の臨床試験市場規模:疾患別(自己免疫・炎症、疼痛処理、腫瘍、糖尿病、肥満、その他)
・世界の臨床試験市場規模:地域別
・競争分析
【レポートの概要】

Clinical Trials Market Growth & Trends

The global clinical trials market size is expected to reach USD 69.3 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.7% from 2021 to 2028. An increase in the volume and complexity of clinical trials has been witnessed lately, which plays an important role in the R&D of new drugs and other products. The market witnessed a decline of 6.0% in 2020 owing to the COVID-19 pandemic. However, the market is projected to recover from 2021 onwards. Also, clinical trials have become increasingly costly ventures, adding to the overall cost of developing a drug. Hence, big pharmaceuticals and small biotechnology firms are looking for innovative ways to improve trial outcomes and decrease operational costs.

The increasing need to develop new therapeutics for chronic diseases such as cancer, respiratory disorder, diabetes, cardiovascular disease, and others is creating immense pressure on healthcare. The global pandemic caused due to COVID-19 and the increasing demand for developing a suitable treatment for the same is driving the market’s growth. The number of people affected by the coronavirus has reached one million, which further depicts an increasing need for therapeutics and vaccines. Currently, there are 288therapeutics and 106 vaccines in development. Out of this, nearly 7.0% of therapeutics are in Phase IV, 21.0% in Phase III, and 43.0% and 13.0% in Phase II and Phase I respectively.

The pandemic has also resulted in the global disruption of traditional onsite clinical trials. Hence, regulatory bodies all over the world have launched various initiatives for fast-tracking clinical trials for the development of innovative solutions. One such instance is Solidarity, an international clinical trial launched by the WHO to find effective treatment against COVID-19.

Though COVID-19 is forcing many medical device and drug developers to revise the approach they prepare for these types of crises, integrating best practices within clinical trial procedures and adapting to virtual trials can support the continuous development of therapeutics even in the presence of this pandemic.

Clinical Trials Market Report Highlights

• The phase III segment dominated the market and accounted for the largest revenue share of 53.2% in 2020. This is attributed to the complexity level associated with this phase

• The interventional segment accounted for the largest revenue share of 82.1% in 2020 owing to the increasing demand for the intervention for clinical trials by researchers

• North America dominated the market and accounted for the largest revenue share of 51.0% in 2020. Favorable government initiatives and the presence of large numbers of players in the U.S. offerings advanced services are responsible for market growth

• In Asia Pacific, the market is expected to expand at the fastest CAGR of 6.7% over the forecast period owing to the increasing patient pool and cost-efficient services

【レポートの目次】

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Phase
1.1.2. Study Design
1.1.3. Indication
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1: Understanding the market dynamics
1.9.2. Objective 2: Understanding the market estimates and forecasts
1.9.3. Objective 3: Understanding the attributes such as strategy framework, competitor categorization
1.9.4. Objective 4: Understanding the key product and application scopes to conclude on the market size
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Clinical Trials Market Variables, Trends & Scope
3.1. Market Lineage outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Product Pipeline Analysis, by Stage
3.3.1. Therapeutics in development
3.3.2. Vaccines in development
3.4. Fast track of clinical trials
3.4.1. FDA initiative – CTPA
3.4.2. U.K. initiative – ACCORD
3.4.3. ASIA Pacific initiative – DCGI
3.4.4. University of Pittsburgh School of Medicine-UPMC
3.5. Solidarity clinical trials
3.5.1. Participation in solidarity trials
3.5.2. Solidarity clinical trial for vaccines
3.6. Virtual clinical trials
3.6.1. In-home clinical services
3.7. COVID-19 impact on clinical trials
3.7.1. Companies with phase 1 trial disruption
3.7.2. Companies with phase 2 trial disruption
3.7.3. Companies with phase 3 trial disruption
3.8. Market Dynamics
3.8.1. Market Driver Analysis
3.8.1.1. Increasing research and development promoting outsourcing
3.8.1.2. Adoption of new technology in clinical research
3.8.1.3. Increasing prevalence of chronic disease
3.8.1.4. Globalization of clinical trials
3.8.2. Market Restraint Analysis
3.8.2.1. Stringent regulatory policies for patient enrollment
3.8.2.2. Lack of skilled workforce in clinical research
3.8.3. Industry Challenges
3.8.3.1. Rising cost of clinical trial
3.9. Clinical Trials: Market Analysis Tools
3.9.1. Industry Analysis – Porter’s
3.9.1.1. Supplier Power
3.9.1.2. Buyer Power
3.9.1.3. Substitution Threat
3.9.1.4. Threat from new entrant
3.9.1.5. Competitive rivalry
3.9.2. PESTEL Analysis
3.9.2.1. Political Landscape
3.9.2.2. Environmental Landscape
3.9.2.3. Social Landscape
3.9.2.4. Technology Landscape
3.9.2.5. Legal Landscape
3.9.3. Major Deals & Strategic Alliances Analysis
Chapter 4. Clinical Trials Market: Segment Analysis, By Phase, 2016-2028 (USD Million)
4.1. Definitions & Scope
4.2. Phase market share analysis, 2020 & 2028
4.3. Segment Dashboard
4.4. Global Clinical Trials Market, by Phase, 2016 to 2028
4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2028for the following
4.5.1. Phase I
4.5.2. Phase II
4.5.3. Phase III
4.5.4. Phase IV
Chapter 5. Clinical Trials Market: Segment Analysis, By Study Design, 2016 – 2028 (USD Million)
5.1. Definitions & Scope
5.2. Study Design Market Share Analysis, 2020 & 2028
5.3. Segment Dashboard
5.4. Global Clinical Trials Market, By Study Design, 2016 to 2028
5.5. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
5.5.1. Interventional
5.5.2. Observational
5.5.3. Expanded Access
Chapter 6. Clinical Trials Market: Segment Analysis, By Indication, 2016 – 2028 (USD Million)
6.1. Definitions & Scope
6.2. Indication Market Share Analysis, 2020 & 2028
6.3. Segment Dashboard
6.4. Global Clinical Trials Market, By Indication, 2016 to 2028
6.5. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
6.5.1. Autoimmune/inflammation
6.5.2. Pain management
6.5.3. Oncology
6.5.4. CNS condition
6.5.5. Diabetes
6.5.6. Obesity
6.5.7. Cardiovascular
6.5.8. Others
Chapter 7. Clinical Trials Market: Segment Analysis, Indication By Study Design, 2016 – 2028 (USD Million)
7.1. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
7.1.1. Autoimmune/inflammation
7.1.1.1. Interventional
7.1.1.2. Observational
7.1.1.3. Expanded Access
7.1.2. Pain management
7.1.2.1. Interventional
7.1.2.2. Observational
7.1.2.3. Expanded Access
7.1.3. Oncology
7.1.3.1. Interventional
7.1.3.2. Observational
7.1.3.3. Expanded Access
7.1.4. CNS condition
7.1.4.1. Interventional
7.1.4.2. Observational
7.1.4.3. Expanded Access
7.1.5. Diabetes
7.1.5.1. Interventional
7.1.5.2. Observational
7.1.5.3. Expanded Access
7.1.6. Obesity
7.1.6.1. Interventional
7.1.6.2. Observational
7.1.6.3. Expanded Access
7.1.7. Cardiovascular
7.1.7.1. Interventional
7.1.7.2. Observational
7.1.7.3. Expanded Access
7.1.8. Others
7.1.8.1. Interventional
7.1.8.2. Observational
7.1.8.3. Expanded Access
Chapter 8. Clinical Trials Market: Regional Market Analysis, By Phase, By Study Design, By Indication, 2016 – 2028 (USD Million)
8.1. Definitions & Scope
8.2. Regional Market Share Analysis, 2020 & 2028
8.3. Regional Market Dashboard
8.4. Regional Market Share, 2020
8.5. Market Size, & Forecasts, and Trend Analysis, 2016 to 2028:
8.6. North America
8.6.1. Market estimates and forecast, by country, 2016 – 2028 (USD Million)
8.6.2. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.6.3. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.6.4. Market estimates and forecast, By Indication, 2016 – 2028 (USD Million)
8.6.5. U.S.
8.6.5.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.6.5.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.6.5.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
8.6.6. Canada
8.6.6.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.6.6.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.6.6.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
8.7. Europe
8.7.1. Market estimates and forecast, by country, 2016 – 2028 (USD Million)
8.7.2. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.7.3. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.7.4. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
8.7.5. Germany
8.7.5.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.7.5.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.7.5.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
8.7.6. U.K.
8.7.6.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.7.6.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.7.6.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
8.7.7. France
8.7.7.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.7.7.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.7.7.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
8.7.8. Italy
8.7.8.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.7.8.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.7.8.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
8.7.9. Spain
8.7.9.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.7.9.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.7.9.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
8.8. Asia Pacific
8.8.1. Market estimates and forecast, by country, 2016 – 2028 (USD Million)
8.8.2. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.8.3. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.8.4. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
8.8.5. China
8.8.5.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.8.5.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.8.5.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
8.8.6. Japan
8.8.6.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.8.6.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.8.6.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
8.8.7. India
8.8.7.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.8.7.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.8.7.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
8.8.8. Australia
8.8.8.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.8.8.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.8.8.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
8.8.9. South Korea
8.8.9.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.8.9.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.8.9.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
8.9. Latin America
8.9.1. Market estimates and forecast, by country, 2016 – 2028 (USD Million)
8.9.2. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.9.3. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.9.4. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
8.9.5. Brazil
8.9.5.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.9.5.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.9.5.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
8.9.6. Mexico
8.9.6.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.9.6.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.9.6.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
8.9.7. Argentina
8.9.7.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.9.7.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.9.7.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
8.9.8. Colombia
8.9.8.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.9.8.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.9.8.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
8.10. Middle East and Africa
8.10.1. Market estimates and forecast, by country, 2016 – 2028 (USD Million)
8.10.2. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.10.3. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.10.4. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
8.10.5. South Africa
8.10.5.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.10.5.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.10.5.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
8.10.6. Saudi Arabia
8.10.6.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.10.6.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.10.6.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
8.10.7. UAE
8.10.7.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
8.10.7.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
8.10.7.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
Chapter 9. Clinical Trials Market – Competitive Analysis
9.1. Key companies profiled
9.1.1. IQVIA
9.1.1.1. Company Overview
9.1.1.2. Financial Performance
9.1.1.3. Product Benchmarking
9.1.1.4. Strategic Initiatives
9.1.2. PAREXEL International Corporation
9.1.2.1. Company Overview
9.1.2.2. Financial Performance
9.1.2.3. Product Benchmarking
9.1.2.4. Strategic Initiatives
9.1.3. Pharmaceutical Product Development, LLC
9.1.3.1. Company Overview
9.1.3.2. Financial Performance
9.1.3.3. Product Benchmarking
9.1.3.4. Strategic Initiatives
9.1.4. Charles River Laboratory
9.1.4.1. Company Overview
9.1.4.2. Financial Performance
9.1.4.3. Product Benchmarking
9.1.4.4. Strategic Initiatives
9.1.5. ICON Plc
9.1.5.1. Company Overview
9.1.5.2. Financial Performance
9.1.5.3. Product Benchmarking
9.1.5.4. Strategic Initiatives
9.1.6. Wuxi AppTec Inc
9.1.6.1. Company Overview
9.1.6.2. Financial Performance
9.1.6.3. Product Benchmarking
9.1.6.4. Strategic Initiatives
9.1.7. PRA Health Sciences
9.1.7.1. Company Overview
9.1.7.2. Financial Performance
9.1.7.3. Product Benchmarking
9.1.7.4. Strategic Initiatives
9.1.8. SGS SA
9.1.8.1. Company Overview
9.1.8.2. Financial Performance
9.1.8.3. Product Benchmarking
9.1.8.4. Strategic Initiatives
9.1.9. Syneos Health
9.1.9.1. Company Overview
9.1.9.2. Financial Performance
9.1.9.3. Product Benchmarking
9.1.9.4. Strategic Initiatives
9.1.10. Chiltern International Ltd
9.1.10.1. Company Overview
9.1.10.2. Financial Performance
9.1.10.3. Product Benchmarking
9.1.10.4. Strategic Initiatives
9.1.11. Eli Lilly and Company
9.1.11.1. Company Overview
9.1.11.2. Financial Performance
9.1.11.3. Product Benchmarking
9.1.11.4. Strategic Initiatives
9.1.12. Novo Nordisk A/S
9.1.12.1. Company Overview
9.1.12.2. Financial Performance
9.1.12.3. Product Benchmarking
9.1.12.4. Strategic Initiatives
9.1.13. Pfizer
9.1.13.1. Company Overview
9.1.13.2. Financial Performance
9.1.13.3. Product Benchmarking
9.1.13.4. Strategic Initiatives
9.1.14. Clinipace
9.1.14.1. Company Overview
9.1.14.2. Financial Performance
9.1.14.3. Product Benchmarking
9.1.14.4. Strategic Initiatives


List of Tables

Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 3 Therapeutics in development
Table 4 Vaccines in development
Table 5 Vaccines in development for COVID-19
Table 6 Impact of COVID-19 on new patients entering trials
Table 7 Impact of COVID-19 on other therapeutic areas
Table 8 Strategic collaborations by key players
Table 9 Interventional studies
Table 10 Blood cancer clinical trials
Table 11 Medicines in development for neurological disorders, 2018
Table 12 Number of Alzheimer’s disease clinical trials, by phase
Table 13 Top 10 therapy areas by phase


List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Volume price analysis
Fig. 9 Clinical trials market snapshot (2020)
Fig. 10 Clinical trials market segmentation
Fig. 11 Clinical trials market: Strategy framework
Fig. 12 Parent market outlook
Fig. 13 Related/ancillary market outlook
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Virtual clinical trials
Fig. 16 Companies with affected trials, by size
Fig. 17 Affected trials, by study phase
Fig. 18 Market driver relevance analysis (Current & future impact)
Fig. 19 Market restraint relevance analysis (Current & future impact)
Fig. 20 Porter’s five forces analysis
Fig. 21 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 22 Clinical trials market phase outlook: Segment dashboard
Fig. 23 Clinical trials market: Phase movement analysis
Fig. 24 Phase I market, 2016 - 2028 (USD Million)
Fig. 25 Phase II market, 2016 - 2028 (USD Million)
Fig. 26 Phase III market, 2016 - 2028 (USD Million)
Fig. 27 Phase IV market, 2016 - 2028 (USD Million)
Fig. 28 Clinical trials market study design outlook: Segment dashboard
Fig. 29 Clinical trials market: Study design movement analysis
Fig. 30 Interventional studies market, 2016 - 2028 (USD Million)
Fig. 31 Observational studies market, 2016 - 2028 (USD Million)
Fig. 32 Expanded access studies market, 2016 - 2028 (USD Million)
Fig. 33 Clinical trials market indication outlook: Segment dashboard
Fig. 34 Clinical trials market: Indication movement analysis
Fig. 35 Autoimmune clinical trial by phase, 2020 (%)
Fig. 36 Autoimmune/inflammation market, 2016 - 2028 (USD Million)
Fig. 37 Rheumatoid arthritis clinical trial by phase (%)
Fig. 38 Rheumatoid arthritis market, 2016 - 2028 (USD Million)
Fig. 39 Multiple sclerosis clinical trial by phase (%)
Fig. 40 Multiple sclerosis market, 2016 - 2028 (USD Million)
Fig. 41 Osteoarthritis clinical trials by phase (%)
Fig. 42 Osteoarthritis market, 2016 - 2028 (USD Million)
Fig. 43 Irritable Bowel Syndrome (IBS) market, 2016 - 2028 (USD Million)
Fig. 44 Others market, 2016 - 2028 (USD Million)
Fig. 45 Pain management market, 2016 - 2028 (USD Million)
Fig. 46 Chronic pain clinical trial by phase (%)
Fig. 47 Chronic pain market, 2016 - 2028 (USD Million)
Fig. 48 Acute pain clinical trial by phase (%)
Fig. 49 Acute pain market, 2016 - 2028 (USD Million)
Fig. 50 Oncology market, 2016 - 2028 (USD Million)
Fig. 51 Blood cancer market, 2016 - 2028 (USD Million)
Fig. 52 Solid tumors market, 2016 - 2028 (USD Million)
Fig. 53 Others market, 2016 - 2028 (USD Million)
Fig. 54 CNS conditions market, 2016 - 2028 (USD Million)
Fig. 55 Epilepsy market, 2016 - 2028 (USD Million)
Fig. 56 Parkinson's disease (PD) market, 2016 - 2028 (USD Million)
Fig. 57 Huntington's disease market, 2016 - 2028 (USD Million)
Fig. 58 Stroke market, 2016 - 2028 (USD Million)
Fig. 59 Traumatic Brain Injury (TBI) market, 2016 - 2028 (USD Million)
Fig. 60 Amyotrophic lateral sclerosis (ALS) market, 2016 - 2028 (USD Million)
Fig. 61 Muscle regeneration market, 2016 - 2028 (USD Million)
Fig. 62 Others market, 2016 - 2028 (USD Million)
Fig. 63 Diabetes market, 2016 - 2028 (USD Million)
Fig. 64 Obesity clinical trial by phase (%)
Fig. 65 Obesity market, 2016 - 2028 (USD Million)
Fig. 66 Cardiovascular market, 2016 - 2028 (USD Million)
Fig. 67 Others indications market, 2016 - 2028 (USD Million)
Fig. 68 Autoimmune/inflammation interventional studies market, 2016 - 2028 (USD Million)
Fig. 69 Autoimmune/inflammation observational studies market, 2016 - 2028 (USD Million)
Fig. 70 Autoimmune/inflammation expanded access market, 2016 - 2028 (USD Million)
Fig. 71 Pain management interventional studies market, 2016 - 2028 (USD Million)
Fig. 72 Pain management observational studies market, 2016 - 2028 (USD Million)
Fig. 73 Pain management expanded access market, 2016 - 2028 (USD Million)
Fig. 74 Oncology interventional studies market, 2016 - 2028 (USD Million)
Fig. 75 Oncology observational studies market, 2016 - 2028 (USD Million)
Fig. 76 Oncology expanded access market, 2016 - 2028 (USD Million)
Fig. 77 CNS conditions interventional studies market, 2016 - 2028 (USD Million)
Fig. 78 CNS conditions observational studies market, 2016 - 2028 (USD Million)
Fig. 79 CNS conditions expanded access market, 2016 - 2028 (USD Million)
Fig. 80 Diabetes interventional studies market, 2016 - 2028 (USD Million)
Fig. 81 Diabetes observational studies market, 2016 - 2028 (USD Million)
Fig. 82 Diabetes expanded access market, 2016 - 2028 (USD Million)
Fig. 83 Obesity interventional studies market, 2016 - 2028 (USD Million)
Fig. 84 Obesity observational studies market, 2016 - 2028 (USD Million)
Fig. 85 Obesity expanded access market, 2016 - 2028 (USD Million)
Fig. 86 Cardiovascular interventional studies market, 2016 - 2028 (USD Million)
Fig. 87 Cardiovascular observational studies market, 2016 - 2028 (USD Million)
Fig. 88 Cardiovascular expanded access market, 2016 - 2028 (USD Million)
Fig. 89 Others interventional studies market, 2016 - 2028 (USD Million)
Fig. 90 Others observational studies market, 2016 - 2028 (USD Million)
Fig. 91 Others expanded access market, 2016 - 2028 (USD Million)
Fig. 92 Regional market: Key takeaways
Fig. 93 Regional market share, 2020
Fig. 94 Regional outlook, 2020 & 2028
Fig. 95 North America market, 2016 - 2028 (USD Million)
Fig. 96 U.S. market, 2016 - 2028 (USD Million)
Fig. 97 Canada market, 2016 - 2028 (USD Million)
Fig. 98 Europe market, 2016 - 2028 (USD Million)
Fig. 99 U.K. market, 2016 - 2028 (USD Million)
Fig. 100 Germany market, 2016 - 2028 (USD Million)
Fig. 101 France market, 2016 - 2028 (USD Million)
Fig. 102 Italy market, 2016 - 2028 (USD Million)
Fig. 103 Spain market, 2016 - 2028 (USD Million)
Fig. 104 Asia Pacific market, 2016 - 2028 (USD Million)
Fig. 105 India market, 2016 - 2028 (USD Million)
Fig. 106 Japan market, 2016 - 2028 (USD Million)
Fig. 107 China market, 2016 - 2028 (USD Million)
Fig. 108 Australia market, 2016 - 2028 (USD Million)
Fig. 109 South Korea market, 2016 - 2028 (USD Million)
Fig. 110 Latin America market, 2016 - 2028 (USD Million)
Fig. 111 Brazil market, 2016 - 2028 (USD Million)
Fig. 112 Mexico market, 2016 - 2028 (USD Million)
Fig. 113 Argentina market, 2016 - 2028 (USD Million)
Fig. 114 Colombia market, 2016 - 2028 (USD Million)
Fig. 115 MEA market, 2016 - 2028 (USD Million)
Fig. 116 South Africa market, 2016 - 2028 (USD Million)
Fig. 117 Saudi Arabia market, 2016 - 2028 (USD Million)
Fig. 118 UAE market, 2016 - 2028 (USD Million)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の臨床試験市場2021-2028:フェーズ別(フェーズ1、フェーズ2、フェーズ3、フェーズ4)、研究デザイン別(介入性、観察、拡張アクセス)、疾患別、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆